CHAIR (C–H Activation for Industrial Renewal) is a €4 m Marie Curie ITN project gathering 15 academic and industrial research laboratories across Europe, offering 15 collaborative PhD scholarship on C–H activation.🕸️ chair-itn.eu🦜twitter.com/chair_itn📼 youtube.com/@chair-itnMy job as the European Project Manager is to make sure the project runs smoothly.Key tasks include:- animating the network (virtual monthly meetings and in-person event organisation);- providing support to the PIs and PhD students through logistic and administrative issues;- ensuring a regular communication with the EC, including the preparation of the deliverables and periodic/final reporting;- managing the consortium's pooled budget;- creating and implementing the project communication strategy;- designing the Data Management Plan and ensuring its implementation.

Turning raw ideas into structured, clear and concise grant applications (French and English). I am specialised in technical writing and work in partnership with financial experts.My services range from proof-reading to complete write-ups, and covers formats such as grant applications, communication presentations, scientific and technical documents.

A short contract during which I represented the biohydrogen team from the RePSeM group (Recognition and Molecular Separation Processes), IPHC UMR 7178. I performed a comprehensive analysis of the European hydrogen research landscape and identified potentiel key partners to form a consortium. I identified relevant research calls, and led the creation of a consortium and the write-up of a collaborative Horizon Europe project.

International consultancy for innovative companies.I helped startups define their innovation project and prepared technical funding applications both in French and English: BPI loans, i-Lab, Concours Innovation, Innovate UK, Horizon 2020 (SME Instrument).Moreover, I became strongly involved in growing the company's activity and online presence. I took the lead in marketing and communication activities both:- online: I rebuilt the company's website, generated content (in-depth analysis of funding instruments, infographics, blog posts), and set-up a newsletter;- and offline: by organising events and delivering presentations on how to access innovative funding.Finally, I was involved in HR activities, recruiting and training new team members and interns.

Dedicated research work to explore the potential for small molecules, called foldamers, to mimic portions of proteins’ 3D shape and behaviour, towards generating hybrid “bionic” proteins, with a long-term aim of developing new therapeutics.Full abstract:De novo design of foldamers is a current challenge of chemical biology, and overcoming it is essential to expand the protein toolbox. α-helix mimicry is a key approach to building foldamers and a stepping-stone towards generating "bionic proteins", i.e. proteins comprising non-natural segments, with enhanced biological functions. As part of this aim, my work as a PhD student in the Wilson Group focused on using proteomimetics to build novel 3-dimensional constructs.As a groundwork towards generating proteomimetic-based coiled coils, I designed and synthesised small aromatic oligoamides and carried out extensive NMR studies to assess their ability to form supramolecular complexes through self-assembly. I also investigated the interactions between aromatic oligoamides and Affimers, a non-antibody-based scaffold developped in the BioScreening and Technology Group at the University of Leeds. In tandem with phage display, I screened a library of Affimers against a small library of biotinylated N-alkylated proteomimetics and characterised several types of recognitions with ELISA and Fluorescence Anisotropy.I presented my results at internal and international conferences and published 2 first-author papers.

For three hours a week, I supervised undergraduate students (60 per session), ensured their safety in the laboratory, marked their experimental work and theoretical exercises.

Towards the total synthesis of linear analogues of (+)-­aR,11S­‐myricanol, I optimised key steps of an established pathway, including stereoselective synthesis.

Synthesis and characterisation of novel drug targets.